Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:DMED)

0.0800 -0.0100 (-11.11%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DMED

< Previous 1 2 Next >
DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO
BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution
Potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Test Launch of CERVAI™ Brain Health in University Brain Health Center
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Pilot Launch of CERVAI™ Brain Health AI Solution
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Accelerates Commercialization of CERVAI™ Brain Health AI Platform with Acceptance into the SOPHIE Program
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Launches New Healthcare Provider Network Program for CERVAI™ Brain Health AI Platform in Canada and the USA
Program provides healthcare providers access to Diagnamed’s novel brain health AI platform 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Provides Update for its Brain Health AI Platform, CERVAI™
A world first, CERVAI™ on track for commercialization in Q4-2023 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Provides Update on CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ entering final development stage and readying for commercialization in Q4-2023 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Launches PalGPT.ai, a Generative AI Brain Health Solution
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces DTC Eligibility of Its Common Shares in the United States
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Launches “Health GenAI”, a New Division for Generative AI Healthcare Solutions
Focused on Health GenAI and CERVAI™, a generative AI brain health platform 
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Launches FormGPT.io, a Generative AI Healthcare Solution
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Enters into License Agreement with University of Miami for Brain Health Platform for Integration with CERVAI™, a Brain Health AI Platform Leveraging Generative AI
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023 
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Holdings Incorporates OpenAI’s ChatGPT into BRAIN AGE™ AI Product Suite
Brain Health Digital Platform to be available in May 2023 
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023
From Diagnamed Holdings Corp.
Via GlobeNewswire
DiagnaMed Holdings Acquires Exclusive Rights to a Virtual Reality and Artificial Intelligence-based Neurodiagnostic System for Neurodegenerative Disease
From Diagnamed Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.